Shots:

• The NMPA has approved Pusintin for marketing in mainland China (Ex-Hong Kong, Macau, and Taiwan regions) for the treatment of patients with advanced, metastatic, or recurrent nsq.NSCLC  and mCRC
• In non-clinical/ clinical studies, Pusintin showed similar PK characteristics as originator drug and clinically equivalent with high similarity in safety and immunogenicity
• Pusintin marks the 1st marketing-approved biosimilar of Avastin in China. The company has commercial-scale manufacturing operations in Suzhou Industrial Park. For Pusintin, company acquires the Perfusion-batch mixed culture technology (PB-Hybrid Technology) for commercial production

Ref: PR Newswire | Image: Tot Biopharm